Company Description
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe.
The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.
The company was incorporated in 1993 and is headquartered in Montreal, Canada.
| Country | Canada |
| Founded | 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Paul Lévesque |
Contact Details
Address: 2015 Peel Street, 11th Floor Montreal, QC H3A 1T8 Canada | |
| Phone | 514 336 7800 |
| Website | theratech.com |
Stock Details
| Ticker Symbol | THTX |
| Exchange | NASDAQ |
| Fiscal Year | December - November |
| Reporting Currency | USD |
| CIK Code | 0001512717 |
| CUSIP Number | 88338H100 |
| ISIN Number | CA88338H7040 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Lévesque | President, Chief Executive Officer and Director |
| Philippe Dubuc M.B.A., MBA | Senior Vice President and Chief Financial Officer |
| Jocelyn Lafond L.L.M., LL.B. | General Counsel and Corporate Secretary |
| Dr. Christian Marsolais Ph.D. | Senior Vice President and Chief Medical Officer |
| John Leasure | Global Commercial Officer |
| Hon. Andre Dupras M.Sc. | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | 6-K | Report of foreign issuer |
| Dec 12, 2024 | 6-K | Report of foreign issuer |
| Dec 11, 2024 | 6-K | Report of foreign issuer |
| Dec 9, 2024 | 6-K | Report of foreign issuer |
| Dec 5, 2024 | 6-K | Report of foreign issuer |
| Dec 4, 2024 | 6-K | Report of foreign issuer |
| Dec 4, 2024 | 6-K | Report of foreign issuer |
| Dec 2, 2024 | 6-K | Report of foreign issuer |
| Nov 26, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |